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Abstract
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Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs'
brain tissue, which has potential neuroprotective and neurotrophic properties. It is widely used
in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian
and post-Soviet  countries.  Objectives:  To assess  the benefits  and risks  of  cerebrolysin  for
treating acute ischaemic stroke.  Search methods:  In May 2016 we searched the Cochrane
Stroke Group Trials Register, CENTRAL, MEDLINE, Embase, Web of Science Core Collection, with
Science  Citation  Index,  LILACS,  OpenGrey,  and  a  number  of  Russian  Databases.  We  also
searched reference lists, ongoing trials registers and conference proceedings, and contacted the
manufacturer of cerebrolysin, EVER Neuro Pharma GmbH (formerly Ebewe Pharma). Selection
criteria: Randomised controlled trials (RCTs) comparing cerebrolysin, started within 48 hours of
stroke onset and continued for any time, with placebo or no treatment in people with acute
ischaemic  stroke.  Data  collection  and  analysis:  Two review authors  independently  applied
inclusion criteria, assessed trial quality and risk of bias, and extracted data. Main results: We
identified six RCTs (1501 participants) that met the inclusion criteria. We evaluated risk of bias
and judged it to be unclear for generation of allocation sequence in four studies and low in two
studies;  unclear  for  allocation concealment  in  five studies  and low in  one study;  high for
incomplete outcome data (attrition bias) in five studies and unclear in one study; unclear for
blinding; high for selective reporting in four studies and unclear in two; and high for other
sources of bias in three studies and unclear in the rest. The manufacturer of cerebrolysin,
pharmaceutical  company EVER Neuro Pharma,  supported three multi-centre studies,  either
totally,  or  providing  cerebrolysin  and  placebo,  randomisation  codes,  research  grants,  or
statisticians. None of the included trials reported on poor functional outcome defined as death
or dependence at the end of the follow-up period or early death (within two weeks of stroke
onset). All-cause death: we extracted data from five trials (1417 participants). There was no
difference in the number of deaths: 46/714 in cerebrolysin group versus 47/703 in placebo
group; risk ratio (RR) 0.91 95% confidence interval (CI) 0.61 to 1.35 (5 trials, 1417 participants,
moderate-quality evidence). Serious adverse events: two trials reported on this outcome, with
90% confidence cerebrolysin increased the risks of serious adverse events by at least one third
compared to placebo: 62/589 in cerebrolysin group versus 46/600 in placebo group; RR 1.37
90% CI 1.01 to 1.86 (2 trials, 1189 participants, moderate-quality evidence). Total number of
people with adverse events: three trials reported on this. There was no difference in the total
number of people with adverse events: 308/667 in cerebrolysin group versus 307/668 in placebo
group;  RR  0.97  95% CI  0.86  to  1.09,  random-effects  model  (3  trials,  1335  participants,
moderate-quality evidence). Authors' conclusions: The findings of this Cochrane Review do not
demonstrate clinical  benefits of cerebrolysin for treating acute ischaemic stroke. We found
moderate-quality evidence suggesting that serious adverse events may be more common with
cerebrolysin use in acute ischaemic stroke.
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